Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Contact: Errol Zhou (Mr.) Tel: +86-551-65523315 Mobile/WhatsApp: +86 17705606359 QQ: 196299583 Skype: [email protected] Email: [email protected] Add: 1002, Huanmao Building, No.105, Mengcheng Road, Hefei City, 230061, China Eli Lilly recently announced that detailed results of the Phase 3 SURPASS-4 (NCT03730662) clinical trial evaluating the dual-acting GIP and GLP-1 receptor agonist tirzepatide (LY3298176) for the treatment of type 2 diabetes have been published in top international medical journals "The Lancet" (The Lancet)
Safety and efficacy have not been established
It's important to seek urgent medical attention if you experience severe, persistent abdominal pain (which could indicate pancreatitis, a rare but serious side effect), persistent vomiting leading to dehydration, or symptoms of gallbladder problems whilst taking these medications
The dose and branding are different, but the active ingredient is the same
